Could a vaccine stop breast cancer before it starts? new trial launches
NCT ID NCT06218303
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing whether a vaccine targeting the MUC1 protein, combined with hormone therapy, can help prevent ductal carcinoma in situ (DCIS) from becoming invasive breast cancer. Fifty women with ER-positive DCIS will receive either hormone therapy alone or hormone therapy plus the vaccine before surgery. The main goal is to see if the vaccine boosts the immune system's response against cancer cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MUC1 peptide vaccine combined with Hiltonol® (an immune booster) and hormone therapy (aromatase inhibitor or SERM)
What this could lead to
If it works, this could lead to a vaccine that prevents ductal carcinoma in situ from progressing to invasive breast cancer, reducing the need for surgery.
What could go wrong
This is a very early phase 1 trial with only 50 participants, so it is too small to prove effectiveness. The vaccine may not trigger a strong enough immune response, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCTAL CARCINOMA IN SITU are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Magee Womens Hospital
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••